tiprankstipranks
Trending News
More News >
Blueberries Medical (TSE:BBM)
:BBM

Blueberries Medical (BBM) AI Stock Analysis

Compare
12 Followers

Top Page

TS

Blueberries Medical

(OTC:BBM)

Rating:53Neutral
Price Target:
C$0.00
▼(-100.00%Downside)
Blueberries Medical's overall score reflects significant financial performance challenges, with ongoing losses and cash flow issues. However, the recent capital infusion and technical indicators offer some optimism. The stock valuation remains unattractive, primarily due to negative earnings, making it less appealing for value investors.

Blueberries Medical (BBM) vs. iShares MSCI Canada ETF (EWC)

Blueberries Medical Business Overview & Revenue Model

Company DescriptionBlueberries Medical Corp. (BBM) is a Latin American cannabis company focused on the cultivation, processing, and distribution of medical cannabis products. Operating primarily in Colombia, the company leverages favorable climatic conditions and regulatory frameworks to produce high-quality cannabis derivatives. Blueberries Medical aims to be a leading supplier of cannabis-based health and wellness products in the region, catering to both domestic and international markets.
How the Company Makes MoneyBlueberries Medical makes money through the cultivation and sale of cannabis products, primarily targeting the medical and wellness sectors. The company generates revenue by selling cannabis derivatives such as oils, extracts, and other infused products to pharmaceutical companies, healthcare providers, and wellness brands. Additionally, Blueberries Medical may enter into strategic partnerships or licensing agreements to expand its distribution network and enhance its market reach. Key factors contributing to its earnings include its ability to produce cannabis at a low cost due to Colombia's favorable growing conditions and its compliance with international regulatory standards, enabling access to export markets.

Blueberries Medical Financial Statement Overview

Summary
The company faces significant profitability challenges with negative net profit and cash flow margins despite revenue growth. Operational inefficiencies and cash burn issues are notable, posing risks to financial stability.
Income Statement
45
Neutral
Blueberries Medical has shown some progress in revenue growth but continues to face significant profitability challenges. The gross profit margin has fluctuated but remains low, indicating efficiency issues. The net profit margin is negative, highlighting ongoing losses. Despite revenue growth, the EBIT and EBITDA margins are negative, reflecting operational inefficiencies.
Balance Sheet
50
Neutral
The company's balance sheet indicates a relatively stable equity position, although it has faced declining total assets over recent years. The debt-to-equity ratio is low, suggesting conservative leverage use. However, the return on equity is negative due to net losses, which is a concern. The equity ratio is healthy, showing good asset financing through equity.
Cash Flow
40
Negative
Cash flow analysis reveals significant negative operating cash flow and free cash flow, reflecting ongoing cash burn issues. The free cash flow to net income ratio is concerning, as it indicates inefficiencies in converting net income into cash. The operating cash flow to net income ratio is negative, showing issues in operational cash generation relative to net income.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue471.41K288.27K235.45K138.75K65.98K
Gross Profit59.32K84.22K-17.72K-245.45K62.40K
EBITDA-1.04M-1.22M-811.47K-4.05M-4.11M
Net Income-1.15M-1.64M-917.58K-5.32M-4.98M
Balance Sheet
Total Assets1.38M2.42M3.35M3.59M7.27M
Cash, Cash Equivalents and Short-Term Investments66.08K818.16K1.41M1.34M306.51K
Total Debt11.44K12.80K1.34M1.44M1.49M
Total Liabilities545.61K470.72K1.89M2.16M3.38M
Stockholders Equity834.81K1.95M1.47M1.43M3.89M
Cash Flow
Free Cash Flow-796.85K-1.35M-1.47M-1.73M-3.00M
Operating Cash Flow-796.85K-1.33M-1.47M-1.68M-2.39M
Investing Cash Flow9.00K382.92K101.94K-48.77K-611.04K
Financing Cash Flow-1.95K539.10K1.35M2.77M783.92K

Blueberries Medical Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.02
Price Trends
50DMA
0.01
Positive
100DMA
0.01
Positive
200DMA
0.01
Positive
Market Momentum
MACD
<0.01
Positive
RSI
55.91
Neutral
STOCH
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BBM, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.01, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 55.91 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BBM.

Blueberries Medical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
TSDHB
60
Neutral
C$6.88M181.82-3.45%4.04%80.24%
TSBBM
53
Neutral
C$7.43M-112.06%46.27%20.75%
51
Neutral
C$5.53M80.000.83%-8.84%-96.82%
51
Neutral
$9.13M-63.75%9.34%69.69%
46
Neutral
C$88.06M-971.43%571.23%64.25%
46
Neutral
C$194.28M-4.22-8.60%2.64%13.54%-1.44%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:BBM
Blueberries Medical
0.02
0.00
0.00%
TSE:ATLE
Willow Biosciences Inc
0.25
-0.35
-58.33%
TSE:DHB
Delivra Health Brands
0.22
-0.08
-26.67%
IMCC
IM Cannabis Corp
2.96
0.83
38.97%
TSE:CANB
CanadaBis Capital
0.04
-0.02
-33.33%

Blueberries Medical Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Blueberries Medical Secures C$1 Million for Expansion
Positive
Mar 26, 2025

Blueberries Medical Corp. announced a C$1 million non-brokered private placement to fund and expand its operations. The offering is led by Terraflos Inc., which is exploring expansion in Latin America. This move is expected to enhance Blueberries’ operational capabilities and strengthen its market position in the medicinal cannabis industry.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 18, 2025